Showing 2331-2340 of 3290 results for "".
- Real-World Data Confirm Upadacitinib Effectiveness Across Body Regionshttps://practicaldermatology.com/news/real-world-data-confirm-upadacitinib-effectiveness-across-body-regions/2486450/Real-world evidence from the AD-VISE study demonstrates consistent and robust effectiveness of upadacitinib across body regions in patients with atopic dermatitis (AD), reinforcing outcomes observed in controlled clinical trials, according to data discussed by Melinda Gooderham, MD, MSc, at the A
- Roflumilast Cream Shows Safety and Efficacy in Infants With Atopic Dermatitishttps://practicaldermatology.com/news/roflumilast-cream-shows-safety-and-efficacy-in-infants-with-atopic-dermatitis/2486449/Roflumilast cream 0.05%, a topical phosphodiesterase 4 (PDE4) inhibitor, demonstrated favorable safety and clinically meaningful efficacy in infants with atopic dermatitis (AD), according to results from the Phase 2 INTEGUMENT-INFANT study presented by Lawrence F. Eichenfield, MD, at the American
- Envudeucitinib Outperforms Placebo and Apremilast in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/envudeucitinib-outperforms-placebo-and-apremilast-in-phase-3-psoriasis-trials/2486447/Envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor, demonstrated significant efficacy and a favorable safety profile in patients with moderate-to-severe plaque psoriasis, according to Phase 3 data from the ONWARD 1 and ONWARD 2 trials presented by Andrew Blauvelt, MD, MBA,
- Rezpegaldesleukin Shows Promise in Alopecia Areata in Phase 2b Trialhttps://practicaldermatology.com/news/rezpegaldesleukin-shows-promise-in-alopecia-areata-in-phase-2b-trial/2486426/Rezpegaldesleukin, an IL-2 pathway agonist designed to expand regulatory T cells (Tregs), demonstrated clinical efficacy and a favorable safety profile in patients with severe-to-very-severe alopecia areata (AA), according to Phase 2b REZOLVE-AA data presented by David Rosmarin, MD, at the Americ
- Zumilokibart Shows Rapid Symptom Relief in Atopic Dermatitishttps://practicaldermatology.com/news/zumilokibart-shows-rapid-symptom-relief-in-atopic-dermatitis/2486425/Zumilokibart (APG777), a half-life–extended anti–IL-13 monoclonal antibody, demonstrated rapid and sustained improvements in symptoms and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to Phase 2 APEX Part A results presented by Emma Guttman-Yassky, MD, PhD,
- Oral STAT6 Degrader KT-621 Shows Early Promise in Atopic Dermatitishttps://practicaldermatology.com/news/oral-stat6-degrader-kt-621-shows-early-promise-in-atopic-dermatitis/2486423/A first-in-class oral STAT6 degrader, KT-621, demonstrated early clinical activity, robust biomarker suppression, and a favorable safety profile in adults with moderate-to-severe atopic dermatitis (AD), according to Phase 1b data presented by Mahta Mortezavi, MD, at the American Academy of Dermat
- Prurigo Nodularis Diagnosis Centers on Clinical Recognition, Not Biopsy, Dr. Elmariah Sayshttps://practicaldermatology.com/news/prurigo-nodularis-diagnosis-centers-on-clinical-recognition-not-biopsy-dr-elmariah-says/2486417/A pragmatic, clinically driven approach is necessary for diagnosing prurigo nodularis (PN), and a biopsy is often unnecessary when key features are present, according to a talk by Sarina Elmariah, MD, FAAD, at the 2026 American Academy of Dermatology (AAD) Annual Meeting. “It is these thre
- Prurigo Nodularis Linked to Elevated Cardiovascular Risk, Expanding View of Systemic Diseasehttps://practicaldermatology.com/news/prurigo-nodularis-linked-to-elevated-cardiovascular-risk-expanding-view-of-systemic-disease/2486416/Growing evidence indicates prurigo nodularis (PN) is associated with increased cardiovascular risk, reinforcing the disease’s systemic nature and the potential consequences of untreated inflammation, according to a talk by Shawn Kwatra, MD, at the 2026 American Academy of Dermatology Annual Meeti
- GLP-1 Receptor Agonists Show Complex, Evolving Role in Alopecia Areatahttps://practicaldermatology.com/news/glp-1-receptor-agonists-show-complex-evolving-role-in-alopecia-areata/2486415/The emerging and sometimes contradictory relationship between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and hair disorders, particularly alopecia areata, was the subject of a talk by Natasha Atanaskova Mesinkovska, MD, PhD, at the 2026 American Academy of Dermatology (AAD) Annual Meet
- Deuruxolitinib Produces Progressive Hair Regrowth in Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-produces-progressive-hair-regrowth-in-severe-alopecia-areata/2485553/Deuruxolitinib produced progressive and clinically meaningful scalp hair regrowth in patients with severe alopecia areata, according to “Deuruxolitinib Improves Scalp Hair Regrowth Over Time in Patients With Severe Alopecia Areata,” a poster by Natasha A. Mesinkovska, MD, PhD, et al presented as